KBY Biotech Indexv0.0.34
Search
← Pipeline|COR-9566

COR-9566

Approved
By Corcept
Source: Trial-derived·Trials: 1
Modality
Small Molecule
MOA
HPK1i
Target
TYK2
Pathway
Sphingolipid
Cervical CaHemophilia ADLBCL
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
~Aug 2018
→ ~Nov 2019
Phase 3
~Feb 2020
→ ~May 2021
NDA/BLA
~Aug 2021
→ ~Nov 2022
Approved
Feb 2023
ApprovedCurrent
NCT04218744
2,951 pts·DLBCL
2023-02→TBD·Not yet recruiting
2,951 total pts1 indication
CompletedCurrentUpcoming
Trial Timeline
Approved
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04218744ApprovedDLBCLNot yet recr...2951CfB
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-1944PfizerNDA/BLAAPOC3HPK1i
VoxacilimabPfizerPhase 2TYK2CAR-T BCMA
NVS-6974NovartisPreclinicalCD19HPK1i
MRK-3732Merck & CoPhase 1TYK2PARPi
ABB-7516AbbViePhase 3PD-L1HPK1i
BemanesiranBioNTechPhase 3PLK4HPK1i
BII-5240BiogenPhase 2/3MALT1HPK1i
SemasacituzumabIlluminaPhase 3Nectin-4HPK1i
CRS-6525CRISPR TherapeuticsPhase 2CD20HPK1i
SND-9531SyndaxPhase 3TYK2AuroraAi